Biotech Values

[DewDiligence]

MNTA Major Shareholders

[Updated for SEC filings through 3/10/10.]


The table below shows all shareholders who file Form 13G and
all insiders with a 1%+ stake on a fully-diluted basis (based on
49.1M diluted shares: #msg-42163809). Insider holdings include
restricted stock and options, whether or not vested. Non-insider
holdings other than Novartis are as of 12/31/09 unless otherwise
indicated in the table footnotes. (As a 10% owner on an SEC
reporting basis, Novartis’ filing requirements are the same
as those of insiders.)

 
                             Shares  Stake 
 Novartis                  4,708,679  9.6% 
 T Rowe Price              4,520,273  9.2% 
 BlackRock Inc.            2,782,260  5.7% 
 Visium Asset Mgmt         2,307,096† 4.7% 
 Samana Capital            2,048,303  4.2% 
 Craig Wheeler (CEO)       1,149,678  2.4% 
 G. Venkataraman (SVP, R&D)  631,601  1.3%  
 Alan  Crane (Director)      652,202  1.3% 
 Ram Sasisekharan (Director) 492,344  1.0%  
  
 †As of  1/22/10 (from 13G filing  1/29/09).